Payment overview · 2025
General Payments
$1,281.38
59 reported records · 20 companies
Healthcare provider profile · identity verified
Juan Barroso, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · HIALEAH, FL · NPI 1699863118
Verified facts
What the public records show
CMS Open Payments records show Juan Barroso, M.D. received $1,281.38 in general payments during 2025 across 59 reported records.
Ardelyx, Inc. accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BYETTA as an associated drug or biological on 60 records involving 49 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Byetta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 384 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $180.57 | 14.1% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $150.96 | 11.8% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.60 | 11.8% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $117.61 | 9.2% | 5 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $107.70 | 8.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.89 | 6.5% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $67.24 | 5.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.73 | 4.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.51 | 3.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.81 | 3.3% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $40.00 | 3.1% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $37.11 | 2.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.56 | 2.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.87 | 2.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $28.56 | 2.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.26 | 2.0% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $25.16 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.46 | 1.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.00 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.78 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,281.38 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $180.57 | 8 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $117.61 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $109.80 | 9 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $107.70 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $83.89 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $81.81 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $68.79 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.46 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $67.24 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $57.82 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $46.62 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.51 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.51 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.81 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $41.16 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.89 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.89 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $28.87 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $28.56 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 384 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 183 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 50 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 106 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 192 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 103 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 153 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 19 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 110 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 113 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
192 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BYETTA open payments reported associated product |
CMS Open Payments — General Payments 60 supporting records · 49 recipient NPIs · example record 1206154618 |
Byetta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
183 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
50 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
103 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
153 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
110 | 24 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
384 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 827 | 189 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 797 | 207 |
| Amlodipine Besylate | Amlodipine Besylate | 658 | 159 |
| Losartan Potassium | Losartan Potassium | 627 | 158 |
| Pantoprazole Sodium | Pantoprazole Sodium | 612 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 511 | 109 |
| Trazodone Hcl | Trazodone Hcl | 505 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 466 | 107 |
| Montelukast Sodium | Montelukast Sodium | 421 | 99 |
| Gabapentin | Gabapentin | 396 | 101 |
| Eliquis | Apixaban | 384 | 47 |
| Metformin Hcl | Metformin Hcl | 377 | 99 |
| Ibuprofen | Ibuprofen | 371 | 73 |
| Azithromycin | Azithromycin | 364 | 223 |
| Famotidine | Famotidine | 351 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 341 | 100 |
| Diclofenac Sodium | Diclofenac Sodium | 320 | 61 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 310 | 69 |
| Alprazolam | Alprazolam | 274 | 31 |
| Furosemide | Furosemide | 260 | 49 |
| Clonazepam | Clonazepam | 258 | 38 |
| Celecoxib | Celecoxib | 245 | 56 |
| Mirtazapine | Mirtazapine | 242 | 49 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 233 | 63 |
| Prednisone | Prednisone | 212 | 75 |
| Clonidine Hcl | Clonidine Hcl | 209 | 79 |
| Lisinopril | Lisinopril | 206 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 198 | 57 |
| Baclofen | Baclofen | 197 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 197 | 57 |
| Linzess | Linaclotide | 192 | 39 |
| Memantine Hcl | Memantine Hcl | 191 | 36 |
| Farxiga | Dapagliflozin Propanediol | 183 | 29 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 181 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 36 |
| Glimepiride | Glimepiride | 170 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 42 |
| Ammonium Lactate | Ammonium Lactate | 161 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 37 |
| Ozempic | Semaglutide | 153 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 40 |
| Alendronate Sodium | Alendronate Sodium | 147 | 27 |
| Atenolol | Atenolol | 147 | 38 |
| Ketoconazole | Ketoconazole | 146 | 28 |
| Meclizine Hcl | Meclizine Hcl | 141 | 40 |
| Temazepam | Temazepam | 141 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 140 | 38 |
| Methylprednisolone | Methylprednisolone | 140 | 109 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 132 | 108 |
| Glipizide Er | Glipizide | 132 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | 59 |
| Sertraline Hcl | Sertraline Hcl | 129 | 23 |
| Buspirone Hcl | Buspirone Hcl | 128 | 30 |
| Spironolactone | Spironolactone | 125 | 21 |
| Glipizide | Glipizide | 123 | 33 |
| Potassium Chloride | Potassium Chloride | 123 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 123 | 26 |
| Entresto | Sacubitril/Valsartan | 119 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 26 |
| Mupirocin | Mupirocin | 114 | 50 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 26 |
| Latanoprost | Latanoprost | 111 | 17 |
| Rybelsus | Semaglutide | 110 | 24 |
| Myrbetriq | Mirabegron | 109 | 25 |
| Jardiance | Empagliflozin | 106 | 20 |
| Lorazepam | Lorazepam | 104 | 14 |
| Xarelto | Rivaroxaban | 104 | 15 |
| Mounjaro | Tirzepatide | 103 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 101 | 16 |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 98 | 15 |
| Ssd | Silver Sulfadiazine | 98 | 30 |
| Methocarbamol | Methocarbamol | 97 | 39 |
| Sildenafil Citrate | Sildenafil Citrate | 97 | 12 |
| Meloxicam | Meloxicam | 95 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 95 | 26 |
| Ezetimibe | Ezetimibe | 94 | 28 |
| Allopurinol | Allopurinol | 93 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 93 | 45 |
| Hydrocortisone | Hydrocortisone | 91 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 91 | 25 |
| Januvia | Sitagliptin Phosphate | 91 | 20 |
| Carvedilol | Carvedilol | 86 | 21 |
| Lactulose | Lactulose | 86 | 23 |
| Levofloxacin | Levofloxacin | 82 | 65 |
| Silver Sulfadiazine | Silver Sulfadiazine | 78 | 27 |
| Donepezil Hcl | Donepezil Hcl | 77 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 76 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 17 |
| Folic Acid | Folic Acid | 75 | 21 |
| Nifedipine Er | Nifedipine | 75 | 23 |
| Finasteride | Finasteride | 73 | 20 |
| Clobetasol Propionate | Clobetasol Propionate | 71 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 71 | 11 |
| Simvastatin | Simvastatin | 65 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 65 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 62 | 15 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 62 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 58 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 40 |
| Synthroid | Levothyroxine Sodium | 55 | 15 |
| Eplerenone | Eplerenone | 54 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | suppressed |
| Nystatin | Nystatin | 52 | 21 |
| Timolol Maleate | Timolol Maleate | 52 | suppressed |
| Gemtesa | Vibegron | 50 | 13 |
| Labetalol Hcl | Labetalol Hcl | 50 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 48 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 48 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | suppressed |
| Sucralfate | Sucralfate | 47 | 11 |
| Metronidazole | Metronidazole | 46 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 36 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 45 | suppressed |
| Lubiprostone | Lubiprostone | 45 | 11 |
| Amoxicillin | Amoxicillin | 43 | 32 |
| Ceftriaxone | Ceftriaxone Sodium | 43 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 43 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 13 |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 39 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Ciclopirox | Ciclopirox | 37 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 36 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 12 |
| Azelastine Hcl | Azelastine Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Enulose | Lactulose | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 30 | 12 |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 30 | 18 |
| Valacyclovir | Valacyclovir Hcl | 30 | 23 |
| Benzonatate | Benzonatate | 29 | 22 |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Ofloxacin | Ofloxacin | 29 | 19 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Procto-Med Hc | Hydrocortisone | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Dexilant | Dexlansoprazole | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Naproxen | Naproxen | 27 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | 12 |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 25 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Meropenem | Meropenem | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 16 |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Hydroxyurea | Hydroxyurea | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 16 |
| Metolazone | Metolazone | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Tadalafil | Tadalafil | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 19 | suppressed |
| Nexium | Esomeprazole Magnesium | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Prolia | Denosumab | 19 | 12 |
| Verquvo | Vericiguat | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Terconazole | Terconazole | 16 | 13 |
| Tobramycin | Tobramycin | 16 | 13 |
| Anastrozole | Anastrozole | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Calcipotriene | Calcipotriene | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 12 | suppressed |
| Desoximetasone | Desoximetasone | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Proctosol-Hc | Hydrocortisone | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Byetta | Exenatide | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Proctozone-Hc | Hydrocortisone | 11 | suppressed |
| Repatha Pushtronex | Evolocumab | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,281.38 · 59 records | Ardelyx, Inc. | AIRSUPRA, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE, GEMTESA, IBSRELA, JARDIANCE, LINZESS, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, Natroba, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, REZDIFFRA, Rybelsus, Spinosad, TRELEGY ELLIPTA, XIFAXAN, ZEPBOUND, ZORYVE | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error